|
 The drug, Mavyret, aims to treat hepatitis C genotypes 1 through 6
in previously untreated adults with or without mild cirrhosis, a
type of liver disease, including patients with moderate to severe
kidney disease and those on dialysis.
Mavyret is the only 8-week duration treatment approved for all
hepatitis C genotypes, the FDA said. A standard treatment for
hepatitis C has a duration of 12-weeks or more. http://bit.ly/2vxrKo3
Hepatitis C genotypes, or strains, are genetically distinct groups
of the virus.
Hepatitis C is a viral disease that causes inflammation of the liver
and can lead to diminished organ function or liver failure.
An estimated 2.7 million to 3.9 million people in the United States
have chronic hepatitis C infection, according to the Centers for
Disease Control and Prevention.
[to top of second column] |
(Reporting by Divya Grover in Benagluru; Editing by Sriraj Kalluvila)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
